This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lung cancer and the supporting scientific evidence and updates the 1996 recommendations on this topic. In 1996, the USPSTF recommended against screening for lung cancer (a grade D recommendation). The Task Force now uses an explicit process in which the balance of benefits and harms is determined exclusively by the quality and magnitude of the evidence. As a result, current letter grades are based on different criteria than those used in 1996. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic, available through the USPSTF Web site (www.preventiveservices .ahrq.gov) and the National Guideline Clearinghouse (www.guideline .gov). The complete USPSTF recommendation statement (which includes a brief review of the supporting evidence) and the summary of the evidence are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov).
SUMMARY OF THE RECOMMENDATION
The U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low-dose computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests. This is a grade I recommendation. ( 
CLINICAL CONSIDERATIONS
The benefit of screening for lung cancer has not been established in any group, including asymptomatic high-risk populations such as older smokers. The balance of harms and benefits becomes increasingly unfavorable for persons at lower risk, such as nonsmokers.
The sensitivity of LDCT for detecting lung cancer is 4 times greater than the sensitivity of CXR. However, LDCT is also associated with a greater number of false-positive results, more radiation exposure, and increased costs compared with CXR.
Because of the high rate of false-positive results, many patients will undergo invasive diagnostic procedures as a result of lung cancer screening. Although the morbidity and mortality rates from these procedures in asymptomatic individuals are not available, mortality rates due to complications from surgical interventions in symptomatic patients reportedly range from 1.3% to 11.6%; morbidity rates range from 8.8% to 44%, with higher rates associated with larger resections.
Other potential harms of screening are potential anxiety and concern as a result of false-positive tests, as well as possible false reassurance due to false-negative results. However, these harms have not been adequately studied.
The brief review of the evidence that is normally included in USPSTF recommendations is available in the complete recommendation statement on the USPSTF Web site (www.preventiveservices.ahrq.gov).
RECOMMENDATIONS OF OTHERS
Lung cancer screening recommendations from the American Cancer Society (1) can be accessed at www .cancer.org/docroot/PUB/content/PUB_3_8X_American _Cancer_Society_Guidelines_for_the_Early_Detection_of _Cancer_update_2001.asp. The policy of the American Academy of Family Physicians (2) can be accessed at www .aafp.org/x24974.xml. Recommendations from the Canadian Task Force on Preventive Health Care can be accessed through its Web site at www.ctfphc.org. Relevant guidelines on lung cancer screening from other organizations can be accessed through the National Guideline Clearinghouse at www.guideline.gov. 
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